Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

KB001-A, KB003 and KB004. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the company's dependence on Sanofi Pasteur for the development and commercialization of KB001-A; the company's ability to successfully complete further development of its programs; the uncertainties inherent in clinical testing, including time to enroll clinical studies; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2013, the quarterly reports on Form 10-Q filed on May 14, 2013 and August 19, 2013, and the company's other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Cell therapy using patients own bone marrow may present option for heart disease
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Entomology 2012 to present 105 insect symposia in November
4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
5. The Brain Prize 2012 is presented May 9th
6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
9. Coral reef experts to present latest coral reef science during July symposium
10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , a ... introduced the SentiGaze Software Development Kit (SDK). ... applications that use off-the-shelf webcams to track eye movements ... at a monitor. Heatmaps can be used for applications ... of online advertising. The SDK can also be used ...
(Date:2/24/2015)... report analyzes the worldwide markets for Face and Voice Biometrics in ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Middle East ... Latin America . Annual estimates and forecasts are provided for ... provided for these markets. Market data and analytics are derived from ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16
... for Agricultural Research and Development, and the company FARMARABA ... produce Omega 3 using marine plant micro-organisms. The ultimate ... highly valued fatty acid, and then apply them at ... centre, which has proven experience in the biotechnology and ...
... Children living near toxic waste sites in ... Indonesia may experience higher blood lead levels, resulting in a ... retardation, according to a study presented today by Kevin Chatham-Stephens, ... Medicine at Mount Sinai, at the Pediatric Academic Societies (PAS) ...
... than two million people in the United States suffer ... abnormal nerve cell firing in the brain which often ... therapies reduce seizures in about two-thirds of patients, the ... therapy and those who take drugs can experience harmful ...
Cached Biology News:Neiker-Tecnalia and FARMARABA produce Omega 3 using marine plant micro-organisms 2Children living near toxic waste sites experience higher blood lead levels resulting in lower IQ 2
(Date:3/26/2015)... 2015 PAREXEL International Corporation (Nasdaq: ... research organization , announced today that the ... acquire all of the business assets of privately-owned ... of specialized pharmacovigilance services, based in Chandigarh, ... assessment, monitoring, and prevention of adverse effects ...
(Date:3/25/2015)... Russia,s pharmaceutical market is one of the ... to its absolute size, plus a growing economy and ... from Business Monitor International. The Russian market is set ... pharmaceutical market, with growth estimates around 10-15% annually reaching ... About Green Cross Green Cross ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital IQ ... Factual Stock Report coverage on Abattis Bioceuticals Corp ... CSE: ATT): is a specialty biotechnology company with ... licensing and marketing proprietary ingredients, bio-similar compounds, patented ... North America . The company ...
(Date:3/25/2015)... 2015  Point-of-Care Partners, a leading health information ... launched the ePrescribing State Law Capsule -- a ... regulatory requirements in all 50 states and DC.  ... to change rapidly, so we have evolved our ... ultimately patients, need," said Tony Schueth , ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Point-of-Care Partners Launches the ePrescribing State Law Capsule 2
... Most Dramatic ChangesNEW YORK, March 9 As the ... more than 40 percent of executives surveyed from companies ... their companies need to institute significant changes across the ... the results of a new white paper released by ...
... /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: ... therapeutics for heart failure patients, today announced its fourth quarter ... a conference call and live webcast to discuss these financial ... programs at 4:30 p.m. EDT (1:30 p.m. PDT) on March ...
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE Alternext US: SVA), ... announced today that the Chinese government, led by ... Ministry of Finance and the State,Administration of Taxation, ... Ltd.(Sinovac Beijing), high-tech enterprise status.,According to the Enterprise ...
Cached Biology Technology:Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 2Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 3Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 4Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 5Nile Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results and Announces Conference Call on March 10, 2009 2Nile Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results and Announces Conference Call on March 10, 2009 3Nile Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results and Announces Conference Call on March 10, 2009 4Sinovac Biotech Co. Ltd., Sinovac's Beijing Subsidiary, Obtains High-Tech Enterprise Status 2Sinovac Biotech Co. Ltd., Sinovac's Beijing Subsidiary, Obtains High-Tech Enterprise Status 3
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
...
DNA fragmentation factor & Inhibitor of CAD...
Component in MasterPure™ Purification Kits...
Biology Products: